{"id":40272,"date":"2000-11-01T12:02:00","date_gmt":"2000-11-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/acarbose-und-lymphozytaere-kolitis"},"modified":"2000-11-01T12:02:00","modified_gmt":"2000-11-01T11:02:00","slug":"acarbose-und-lymphozytaere-kolitis","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/","title":{"rendered":"Acarbose und lymphozyt\u00e4re Kolitis"},"content":{"rendered":"<p>Die Therapie mit Acarbose (Glucobay) bei Diabetes mellitus ist umstritten (s.a. AMB 1996, 30, 81). Nicht nur, weil der Nutzen dieser Substanz auf klinische Endpunkte schlecht belegt ist, sondern auch, weil die Einnahme von Acarbose sehr h\u00e4ufig zu unerw\u00fcnschten Arzneimittelwirkungen f\u00fchrt: 77% Flatulenz, 33% Diarrh\u00f6, 21% Bl\u00e4hungen und Bauchschmerzen (1). Eine Gruppe von Gastroenterologen aus [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Therapie mit Acarbose (Glucobay) bei Diabetes mellitus ist umstritten (s.a. AMB 1996, 30, 81). Nicht nur, weil der Nutzen dieser Substanz auf klinische Endpunkte schlecht belegt ist, sondern auch, weil die Einnahme von Acarbose sehr h\u00e4ufig zu unerw\u00fcnschten Arzneimittelwirkungen f\u00fchrt: 77% Flatulenz, 33% Diarrh\u00f6, 21% Bl\u00e4hungen und Bauchschmerzen (1). Eine Gruppe von Gastroenterologen aus [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[3886,268,852],"class_list":["post-40272","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acarbose","tag-kolitis","tag-orale-antidiabetika"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acarbose und lymphozyt\u00e4re Kolitis - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acarbose und lymphozyt\u00e4re Kolitis - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Die Therapie mit Acarbose (Glucobay) bei Diabetes mellitus ist umstritten (s.a. AMB 1996, 30, 81). Nicht nur, weil der Nutzen dieser Substanz auf klinische Endpunkte schlecht belegt ist, sondern auch, weil die Einnahme von Acarbose sehr h\u00e4ufig zu unerw\u00fcnschten Arzneimittelwirkungen f\u00fchrt: 77% Flatulenz, 33% Diarrh\u00f6, 21% Bl\u00e4hungen und Bauchschmerzen (1). Eine Gruppe von Gastroenterologen aus [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2000-11-01T11:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Acarbose und lymphozyt\u00e4re Kolitis\",\"datePublished\":\"2000-11-01T11:02:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/\"},\"wordCount\":260,\"keywords\":[\"Acarbose\",\"Kolitis\",\"Orale Antidiabetika\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/\",\"name\":\"Acarbose und lymphozyt\u00e4re Kolitis - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"2000-11-01T11:02:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/acarbose-und-lymphozytaere-kolitis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acarbose und lymphozyt\u00e4re Kolitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acarbose und lymphozyt\u00e4re Kolitis - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/","og_locale":"de_DE","og_type":"article","og_title":"Acarbose und lymphozyt\u00e4re Kolitis - Der Arzneimittelbrief","og_description":"Die Therapie mit Acarbose (Glucobay) bei Diabetes mellitus ist umstritten (s.a. AMB 1996, 30, 81). Nicht nur, weil der Nutzen dieser Substanz auf klinische Endpunkte schlecht belegt ist, sondern auch, weil die Einnahme von Acarbose sehr h\u00e4ufig zu unerw\u00fcnschten Arzneimittelwirkungen f\u00fchrt: 77% Flatulenz, 33% Diarrh\u00f6, 21% Bl\u00e4hungen und Bauchschmerzen (1). Eine Gruppe von Gastroenterologen aus [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2000-11-01T11:02:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Acarbose und lymphozyt\u00e4re Kolitis","datePublished":"2000-11-01T11:02:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/"},"wordCount":260,"keywords":["Acarbose","Kolitis","Orale Antidiabetika"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/","name":"Acarbose und lymphozyt\u00e4re Kolitis - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"2000-11-01T11:02:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/acarbose-und-lymphozytaere-kolitis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Acarbose und lymphozyt\u00e4re Kolitis"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40272"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40272\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}